Article Text

Download PDFPDF
  1. Martin Holtkamp1,
  2. Rob McMurray2,
  3. Rui Sousa3,
  4. Edgar Kockelmann4
  1. 1 Charité – Universitätsmedizin Berlin, Germany
  2. 2 Eisai Europe Ltd
  3. 3 Bial, Portugal
  4. 4 Eisai GmbH, Germany


Purpose To assess retention rate, seizure control and safety/tolerability of eslicarbazepine acetate (ESL) as add-on to antiepileptic monotherapy in everyday clinical practice across eight European countries.

Method Eslicarbazepine acetate in Partial-Onset Seizures (EPOS) was a prospective, non-interventional study conducted in adult patients with uncontrolled partial-onset seizures under antiepileptic monotherapy, whose clinician had previously and independently decided to initiate ESL add-on therapy. Primary endpoint was retention rate after 6 months. Other assessments included responder and seizure freedom rates after 6 months, and safety/tolerability.

Results Overall, 219 patients were included (mean age 45.9 years; 57.5% male). Mean time since epilepsy diagnosis was 12.3 years. Mean ESL dose after titration was 944.8 mg/day (range 428.6–2800.0 mg/day). After 6 months, retention, responder and seizure freedom rates were 82.2% (95% confidence interval [CI] 76.5–87.0%), 81.8% (95% CI 75.5–87.1%) and 39.2% (95% CI 32.2–46.5%), respectively. Adverse events (AEs) were reported for 57 (26.0%) patients (most commonly dizziness [4.6%]); eight (3.7%) patients experienced serious AEs. No AE was reported in >5% of patients.

Conclusion ESL as add-on to antiepileptic monotherapy demonstrated favourable retention and seizure control, and was well tolerated by the majority of adult patients in a real-life setting.

Supported by Eisai.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.